Document:

Exhibit
      10.2

    

    COMMON
      STOCK PURCHASE AGREEMENT

    

    AGREEMENT
      entered
      into as of the 18th
      day of
      July, 2007, by and between Morlex,
      Inc., a Colorado corporation with an address at 31 Pierce Lane, Norwich, Vermont
      05055 (the “Company”) and Michael Miller, an individual with an address at 31
      Pierce Lane, Norwich, Vermont 05055 (the “Purchaser”).

    

    WHEREAS,
      the Purchaser desires to purchase, and the Company desires to sell, an aggregate
      of 50,000 shares (the “Shares”) of the Company’s common stock, par value $.001
      per share (the “Common Stock”) upon the terms and conditions
      hereof.

    

    NOW,
      THEREFORE, in consideration of the premises and the mutual agreements herein
      contained, the Purchaser and the Company hereby agree as follows:

    

    SECTION
      1: SALE OF THE SHARES

    

    1.1
      Sale
      of the Shares.
      Subject
      to the terms and conditions hereof, the Company will sell and deliver to the
      Purchaser and the Purchaser will purchase from the Company, upon the execution
      and delivery hereof, the Shares for a purchase price equal to
      $5,000.

     

    SECTION
      2: CLOSING DATE; DELIVERY

    

    2.1
      Closing
      Date.
      The
      closing of the purchase and sale of the Shares hereunder (the “Closing”) shall
      be held immediately following the execution and delivery of this
      Agreement.

    

    2.2
      Delivery
      at Closing.
      At the
      Closing, the Company will deliver to the Purchaser a stock certificate
      registered in the Purchaser’s name, representing the number of Shares to be
      purchased by Purchaser hereunder, against payment of the purchase price therefor
      as indicated above. 

    

    SECTION
      3: REPRESENTATIONS AND WARRANTIES OF PURCHASER

    

    The
      undersigned Purchaser hereby represents and warrants to the Company as
      follows:

     

    3.1
      Transfer
      of Shares.
      The
      Shares have not been registered under the Securities Act and cannot be sold
      or
      otherwise transferred without an effective registration or an exemption
      therefrom, but may not be sold pursuant to the exemptions provided by Section
      4(1) of the Securities Act or Rule 144 under the Securities Act, in accordance
      with the letter from Richard K. Wulff, Chief
      of
      the Office of Small Business Policy of the Securities and Exchange Commission’s
      Division of Corporation Finance,
      to Ken
      Worm of NASD Regulation, Inc., dated January 21, 2000.

    

    3.2
      Experience.
      The
      undersigned has such knowledge and experience in financial and business matters
      that the undersigned is capable of evaluating the merits and risks of investment
      in the Company and of making an informed investment decision. The undersigned
      has adequate means of providing for the undersigned's current needs and possible
      future contingencies and the undersigned has no need, and anticipates no need
      in
      the foreseeable future, to sell the Shares for which the undersigned subscribes.
      The undersigned is able to bear the economic risks of this investment and,
      consequently, without limiting the generality of the foregoing, the undersigned
      is able to hold the Shares for an indefinite period of time and has sufficient
      net worth to sustain a loss of the undersigned's entire investment in the
      Company in the event such loss should occur. Except as otherwise indicated
      herein, the undersigned is the sole party in interest as to its investment
      in
      the Company, and it is acquiring the Shares solely for investment for the
      undersigned's own account and has no present agreement, understanding or
      arrangement to subdivide, sell, assign, transfer or otherwise dispose of all
      or
      any part of the Shares subscribed for to any other person. 

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    3.3
      Investment;
      Access to Data.
      The
      undersigned has carefully reviewed and understands the risks of, and other
      considerations relating to, a purchase of the Common Stock and an investment
      in
      the Company. The undersigned has been furnished materials relating to the
      Company, the private placement of the Common Stock or anything else that it
      has
      requested and has been afforded the opportunity to ask questions and receive
      answers concerning the terms and conditions of the offering and obtain any
      additional information which the Company possesses or can acquire without
      unreasonable effort or expense. Representatives of the Company have answered
      all
      inquiries that the undersigned has made of them concerning the Company, or
      any
      other matters relating to the formation and operation of the Company and the
      offering and sale of the Common Stock. The
      undersigned has not been furnished any offering literature other than the
      materials that the Company may have provided at the request of the undersigned;
      and the undersigned has relied only on such information furnished or made
      available to the undersigned by the Company as described in this Section. The
      undersigned is acquiring the Shares for investment for the undersigned's own
      account, not as a nominee or agent and not with the view to, or for resale
      in
      connection with, any distribution thereof. The undersigned acknowledges that
      the
      Company is a start-up company with no current operations, assets or operating
      history, which may possibly cause a loss of Purchaser’s entire investment in the
      Company. The undersigned acknowledges significant knowledge concerning the
      Company by virtue of being a director of the Company.

    

    3.4
      Authorization.
      (a)
      This Agreement, upon execution and delivery thereof, will be a valid and binding
      obligation of Purchaser, enforceable in accordance with its terms, subject
      to
      applicable bankruptcy, insolvency, reorganization and moratorium laws and other
      laws of general application affecting enforcement of creditors' rights
      generally.

    

    (b)
      The
      execution, delivery and performance by Purchaser of this Agreement and
      compliance therewith and the purchase and sale of the Shares will not result
      in
      a violation of and will not conflict with, or result in a breach of, any of
      the
      terms of, or constitute a default under, any provision of state or Federal
      law
      to which Purchaser is subject, or any mortgage, indenture, agreement,
      instrument, judgment, decree, order, rule or regulation or other restriction
      to
      which the Purchaser is a party or by which the undersigned Purchaser is bound,
      or result in the creation of any mortgage, pledge, lien, encumbrance or charge
      upon any of the properties or assets of Purchaser pursuant to any such
      term.

    

    3.5
      Accredited
      Investor.
      Purchaser is an accredited investor as defined in Rule 501(a) of Regulation
      D
      under the Securities Act of 1933, as amended.

    

    SECTION
      4: MISCELLANEOUS

    

    4.1
      Governing
      Law.
      This
      Agreement shall be governed in all respects by the laws of the State of
      Colorado, without regard to conflicts of laws principles thereof.

    

    4.2
      Survival.
      The
      terms, conditions and agreements made herein shall survive the Closing.

    

    4.3
      Successors
      and Assigns.
      Except
      as otherwise expressly provided herein, the provisions hereof shall inure to
      the
      benefit of, and be binding upon, the successors, assigns, heirs, executors
      and
      administrators of the parties hereto.

    

    4.4
      Entire
      Agreement; Amendment; Waiver.
      This
      Agreement constitutes the entire and full understanding and agreement between
      the parties with regard to the subject matter hereof. Neither this Agreement
      nor
      any term hereof may be amended, waived, discharged or terminated, except by
      a
      written instrument signed by all the parties hereto.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    4.5
      Counterparts.
      This
      Agreement may be executed in any number of counterparts, each of which shall
      be
      an original, but all of which together, shall constitute one
      instrument.

    

    IN
      WITNESS WHEREOF,
      the
      undersigned have hereunto set their hands as of the day and year first above
      written.

    
      	 	 	 
	 	MORLEX,
              INC.
	 
 	 
 	 
 
	 	By:  	/s/
              Michael
              Miller
	 	Name:  	Michael Miller 
	 	Title:  	President 
	 	 	 
	 	PURCHASER
	 	
            
	 	/s/
              Michael Miller  
	 	Michael
              MillerAMENDMENT
      TO REGISTRATION RIGHTS AGREEMENT

     

    This
      Amendment to Registration Rights Agreement (this “Amendment”)
      is made
      and entered into as of July 7, 2007, by and among Calypte Biomedical
      Corporation, a Delaware corporation (the “Company”),
      and
      the investors signatory hereto (each an “Investor”
      and
      collectively, the “Investors”).
      Unless
      otherwise defined herein, all capitalized terms used herein shall have the
      meanings given to them in the Registration Rights Agreement referred to
      below.

     

    WHEREAS,
      the Company and the Investors are parties to a Registration Rights Agreement
      dated as of March 28, 2007 (the "Registration
      Rights Agreement");
      

     

    WHEREAS,
      based on comments the Company received from the Securities and Exchange
      Commission, the parties desire to amend the Registration Rights Agreement to
      delete the requirement that the Registration Statement cover the resale of
      the
      Warrant Shares.

     

    WHEREAS,
      the parties agree to amend and modify the Registration Rights Agreement to
      provide for certain other modifications and amendments agreed to by the parties
      in accordance with the provisions set forth in Section 6(e) of the Registration
      Rights Agreement.

     

    NOW,
      THEREFORE, for good and valuable consideration, the receipt and sufficiency
      of
      which are hereby acknowledged, the Company and each Investor, severally and
      not
      jointly, agree as follows:

     

    
      	
            	1.	
              The
                definition of “Notes” in Section 1 of the Registration Rights Agreement is
                hereby deleted in its entirety.

            

    

     

    
      	
            	2.	
              The
                definition of “Registrable Shares” in Section 1 of the Registration Rights
                Agreement is hereby amended and restated to read in its entirety
                as
                follows:

            

    

     

    “‘Registrable
      Securities’
      means
      the Shares issued or issuable pursuant to the Subscription Agreement, together
      with any securities issued or issuable upon any stock split, dividend or other
      distribution, recapitalization or similar event.”

     

    
      	
            	3.	
              Section
                2(a) of the Registration Rights Agreement is hereby amended and restated
                to read in its entirety as follows:

            

    

     

    “(a)
       On
      or
      prior to each Filing Date, the Company shall prepare and file with the
      Commission a Registration Statement covering the resale of all Registrable
      Securities not already covered by an existing and effective Registration
      Statement for an offering to be made on a continuous basis pursuant to Rule
      415.
      The Registration Statement shall be on Form SB-2 or Form S-3 (except if the
      Company is not then eligible to register for resale the Registrable Securities
      on Form SB-2 or Form S-3, in which case such registration shall be on
      another appropriate form for such purpose) and shall contain (except if
      otherwise required pursuant to written comments received from the Commission
      upon a review of such Registration Statement) the “Plan of Distribution”
attached hereto as Annex
      A.
      The
      Company shall use its best efforts to cause each Registration Statement to
      be
      declared effective under the Securities Act within 120 days following the
      Closing Date and shall use its best efforts to keep each Registration Statement
      continuously effective under the Securities Act until the second year after
      the
      date that the Registration Statement is declared effective by the Commission
      or
      such earlier date when all Registrable Securities covered by the Registration
      Statement have been sold or may be sold without volume restrictions pursuant
      to
      Rule 144(k) as determined by the counsel to the Company pursuant to a written
      opinion letter to such effect, addressed and acceptable to the Company's
      transfer agent and the affected Investors (the “Effectiveness
      Period”).
      The
      initial Registration Statement shall include a number of Registrable Securities
      equal to 100,000,000, the number of Shares issued at the Closing.” 

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

    
      	
            	4.	
              Section
                2(c) of the Registration Rights Agreement is hereby amended and restated
                to read in its entirety as follows:

            

    

     

    “(c)
       If
      a
      Registration Statement is not filed on or prior to its Filing Date (such failure
      being referred to as an “Event,”
      and the
      date on which such Event occurs being referred to as “Event
      Date”),
      then
      in addition to any other rights the Investors may have under applicable law
      or
      at equity: (x) on the Event Date the Company shall pay to each Investor an
      amount, as partial liquidated damages and not as a penalty, equal to 1.0% of
      the
      amount of such Investor’s investment, such payment in cash; and (y) beginning
      with the one (1) month anniversary following each such Event Date, and on each
      monthly anniversary thereafter (if the applicable Event shall not have been
      cured by such date) until the applicable Event is cured, the Company shall
      pay
      to each Investor an amount, as partial liquidated damages and not as a penalty,
      equal to 2.0% of the aggregate amount of such Investor’s investment, such
      payment being in cash. The partial liquidated damages pursuant to the terms
      hereof shall apply on a daily pro-rata basis for any portion of a month prior
      to
      the cure of an Event, including in the case of the first Event Date.”

    

    
      	
            	5.	
              Section
                6(e) of the Registration Rights Agreement is hereby amended and restated
                to read in its entirety as follows:

            

    

     

    “(e)
       Amendments
      and Waivers.
      The
      provisions of this Agreement, including the provisions of this sentence, may
      not
      be amended, modified or supplemented, and waivers or consents to departures
      from
      the provisions hereof may not be given, unless the same shall be in writing
      and
      signed by the Company and the Investors holding at least a majority of the
      Registrable Shares held by the Investors. Notwithstanding the foregoing, a
      waiver or consent to depart from the provisions hereof with respect to a matter
      that relates exclusively to the rights of certain Investors and that does not
      directly or indirectly affect the rights of other Investors may be given by
      Investors of at least a majority of the Registrable Securities to which such
      waiver or consent relates, provided,
      that
      the provisions of this sentence may not be amended, modified, or supplemented
      except in accordance with the provisions of the immediately preceding
      sentence.”

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    
      	
            	6.	
              Except
                for the amendments provided for herein, the Registration Rights Agreement
                shall remain unchanged and in full force and effect.
                

            

    

     

    
      	
            	7.	
              This
                Amendment may be executed in counterparts, each of which shall be
                deemed
                to be an original, but which together shall be deemed to be one and
                the
                same instrument.

            

    

     

    
      	
            	8.	
              This
                Amendment shall be governed by and construed in accordance with the
                laws
                of the State of Oregon without giving effect to the conflicts of
                law
                principles thereof.

            

    

     

    [REMAINDER
      OF PAGE INTENTIONALLY LEFT BLANK

    [SIGNATURE
      PAGE FOR THE COMPANY] 

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    
       

      [SIGNATURE
        PAGE FOR THE COMPANY] 

       

    

    IN
      WITNESS WHEREOF,
      each of
      the parties hereto has caused a counterpart of this Amendment to be duly
      executed and delivered as of the date first above written.

     

    
      	 	 	 
	 	
              Calypte
                Biomedical Corporation 

            
	 
 	 
 	 
 
	
            	By:  	
            
	 	
              

              Signature

            

    

    
    

     

      	 	 	 
	: 	Its:	
            
	 	
              
Title 

    

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    [SIGNATURE
      PAGE FOR INVESTORS]

     

    IN
      WITNESS WHEREOF,
      each of
      the parties hereto has caused a counterpart of this Amendment Agreement to
      be
      duly executed and delivered as of the date first above written.

    
      	 	 	 	 
	
              David
                Khidasheli

            	 	 	
              Mohamed
                Yousif Ahmed Saleh Sulaiman

            
	
              

              Name
                of Investor 

            	 	 	
              

              Name
                of Investor 

            
	 

              

              Signature

            	 	 	 

              

              Signature

            
	 	 	 	 

    

    
      	 	 	 	 
	
              Mohamed
                Ahmed

            	 	 	
              Ahmed
                Abdulla Deemas al Swaidi

            
	
              

              Name
                of Investor 

            	 	 	
              

              Name
                of Investor 

            
	 

              

              Signature

            	 	 	 

              

              Signature

            

    

     

    
      
         

      

      
        5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]